FDA Advisors Wary of Sanofi’s Lemtrada as First-Line MS Drug

A A
A panel of FDA advisors Nov. 14 overwhelmingly voted against approval of Sanofi’s Lemtrada for an expanded indication to treat relapsing multiple sclerosis (MS).

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00